Wound care technology developer Imbed Biosciences has announced the appointment of Terry Bromley as its new chief executive officer (CEO).
With a career spanning over three decades in the medical device and regenerative medicine sectors, Bromley’s ‘expertise’ is expected to contribute to the company’s growth and uphold its commitment to enhancing patient outcomes through soft tissue repair solutions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Imbed Biosciences founder and chief scientific officer Ankit Agarwal said: “Terry brings a wealth of commercial leadership experience in the wound and skin care sector, delivering innovation and building high-performing teams.
“His expertise will be invaluable as we navigate the next phase of our company’s growth with our Microlyte Matrix technology platform. I’m excited to welcome Terry to the Imbed Biosciences family.”
Before his recent appointment at Imbed, Bromley held the position of Avita Medical’s commercial operations and global sales senior vice-president (SVP).
In this role, he spearheaded the regenerative tissue commercial teams and was pivotal in expanding the company’s commercial capabilities both in the US and internationally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHis experience also includes working as Crawford Healthcare’s SVP and general manager, where he was pivotal in establishing and commercialising the US business unit within the wound and skin care markets.
Additionally, his previous roles included senior director of marketing and business development in Emergent BioSolutions’ healthcare protective products division.
After spending nearly two decades at ConvaTec, a unit of Bristol Myers Squibb, Bromley progressed through various leadership roles and was instrumental in steering strategic portfolio and commercialisation initiatives, particularly for the unit’s wound and burn care technologies.
Bromley said: “Imbed’s differentiated platform technology uniquely positions the company to make a meaningful impact on the healthcare industry.”
Leveraging its Microlyte Matrix technology platform, Imbed aims to provide solutions to address local pain and infections in complex wounds.
